Inclacumab
Sign in to saveInclacumab (also known as LC-1004-002, RO4905417, and PF-07940370) is an investigational monoclonal antibody originally developed by Roche for cardiovascular disease and later acquired by Global Blood Therapeutics (GBT), which was subsequently acquired by Pfizer in 2022 for $5.4 billion. It is a fully human monoclonal antibody against P-selectin being developed primarily for the treatment of sickle cell disease with vaso-occlusive crises.
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~4 min read
Encyclopedic overview
8 sectionsContents
- Mechanism of action
- Clinical development
- Phase I studies
- Cardiovascular studies
- Sickle cell disease studies
- Safety profile
- Regulatory status
- References
Inclacumab (also known as LC-1004-002, RO4905417, and PF-07940370) is an investigational monoclonal antibody originally developed by Roche for cardiovascular disease and later acquired by Global Blood Therapeutics (GBT), which was subsequently acquired by Pfizer in 2022 for $5.4 billion. It is a fully human monoclonal antibody against P-selectin being developed primarily for the treatment of sickle cell disease with vaso-occlusive crises.
== Mechanism of action == Inclacumab is a recombinant monoclonal antibody against P-selectin, with potential anti-inflammatory, antithrombotic, and antiatherogenic properties. P-selectin works to mediate leukocyte, platelet, and endothelial interactions through the binding of P-selectin to the P-selectin glycoprotein ligand (PSGL)-1 located on the surface of leukocytes.
Excerpted from Wikipedia’s “Inclacumab” article, available under the CC BY-SA 4.0 licence.